Chugai Pharmaceutical Co. (CHGCY)
(Delayed Data from OTC)
$23.78 USD
+0.07 (0.30%)
Updated Nov 4, 2024 03:59 PM ET
4-Sell of 5 4
C Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CHGCY 23.78 +0.07(0.30%)
Will CHGCY be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CHGCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CHGCY
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run?
CHGCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's Why
Are Medical Stocks Lagging Brookdale Senior Living (BKD) This Year?
Other News for CHGCY
Chugai Pharmaceutical Co., Ltd. 2024 Q3 - Results - Earnings Call Presentation
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q3 2024 Earnings Call Transcript
Roche advances AI-driven cancer diagnostics by expanding its digital pathology open environment
Harding Loevner International Developed Markets Equity Q2 2024 Report
Harding Loevner International Equity ADR Q2 2024 Report